• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[膀胱肿瘤经尿道切除术病例的临床统计]

[Clinical statistics of the bladder tumor--transurethral resection cases].

作者信息

Uchida T, Ao T, Ikeda S, Yokoyama E, Kadowaki K, Shoji K, Koshiba K

机构信息

Department of Urology, Kitasato University School of Medicine.

出版信息

Hinyokika Kiyo. 1990 Sep;36(9):1033-8.

PMID:2239608
Abstract

Two hundred and thirty one patients who underwent transurethral resection of a bladder tumor (TUR-Bt) at our hospital during the past 15 years were analyzed. There were 176 males and 55 females, and the average age at the initial TUR-Bt was 62 years old. Histopathologically, 225 cases were of transitional cell carcinoma, 4 cases of papilloma and 2 cases of squamous cell carcinoma. Grading and staging of 225 transitional cell carcinoma cases revealed grades 1, 2 and 3 in 32, 132 and 21 cases, and stages Ta, T1, T2, T3 and T2-4M1 in 48, 135, 20, 17 and 11 cases, respectively. The frequency of TUR-Bt varied from 1 to 10 times. Among the 231 cases TUR-Bt was done once, twice and three times in 149 (64.5%) and 41 (17.8%), and 22 (9.6%) cases, respectively and the total number of TUR-Bt was 400 times. The duration of the TUR-Bt operation was from 5 min. to 160 min. (mean: 32.4 min.) and the resected weight of tumor between 0.5 g and 85 g (mean: 5.4 g). As a complication of TUR-Bt, TUR-fulguration was necessary to control postoperative bleeding in 7 cases (1.7%), and blood transfusion was required in 13 cases (3.3%) during TUR-Bt. Postoperatively blood transfusion was required in 8 cases (2%), intraperitoneal perforation in 2 cases (0.5%), extraperitoneal perforation in 6 cases (1.5%) and hyponatremia in 1 case (0.3%).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

对过去15年在我院接受经尿道膀胱肿瘤切除术(TUR-Bt)的231例患者进行了分析。其中男性176例,女性55例,初次TUR-Bt时的平均年龄为62岁。组织病理学检查显示,225例为移行细胞癌,4例为乳头状瘤,2例为鳞状细胞癌。225例移行细胞癌病例的分级和分期显示,1级、2级和3级分别有32例、132例和21例,Ta期、T1期、T2期、T3期和T2-4M1期分别有48例、135例、20例、17例和11例。TUR-Bt的次数从1次到10次不等。在231例病例中,TUR-Bt进行1次、2次和3次的分别有149例(64.5%)、41例(17.8%)和22例(9.6%),TUR-Bt的总次数为400次。TUR-Bt手术持续时间为5分钟至160分钟(平均:32.4分钟),切除肿瘤重量为0.5克至85克(平均:5.4克)。作为TUR-Bt的并发症,7例(1.7%)需要进行TUR-电灼以控制术后出血,13例(3.3%)在TUR-Bt期间需要输血。术后8例(2%)需要输血,2例(0.5%)发生腹腔内穿孔,6例(1.5%)发生腹膜外穿孔,1例(0.3%)发生低钠血症。(摘要截选至250字)

相似文献

1
[Clinical statistics of the bladder tumor--transurethral resection cases].[膀胱肿瘤经尿道切除术病例的临床统计]
Hinyokika Kiyo. 1990 Sep;36(9):1033-8.
2
[Prognosis of bladder tumor patients treated by TUR].经尿道膀胱肿瘤切除术治疗的膀胱肿瘤患者的预后
Hinyokika Kiyo. 1989 Sep;35(9):1497-501.
3
[Treatment of 300 patients with bladder cancer].[300例膀胱癌患者的治疗]
Hinyokika Kiyo. 1991 Oct;37(10):1235-41.
4
[Clinical statistics of the bladder tumor--clinical and pathological aspects of 325 cases].膀胱肿瘤的临床统计——325例的临床与病理分析
Hinyokika Kiyo. 1990 Sep;36(9):1015-21.
5
[Changes in grading at bladder tumor recurrence].
Hinyokika Kiyo. 1984 Dec;30(12):1785-91.
6
Urinary fibronectin as a predictor of a residual tumour load after transurethral resection of bladder transitional cell carcinoma.尿纤连蛋白作为膀胱移行细胞癌经尿道切除术后残余肿瘤负荷的预测指标。
BJU Int. 2008 Aug 5;102(5):566-71. doi: 10.1111/j.1464-410X.2008.07637.x. Epub 2008 Apr 11.
7
Organ-sparing treatment in muscle-invasive bladder cancer.肌层浸润性膀胱癌的保留器官治疗。
Strahlenther Onkol. 2005 Oct;181(10):632-7. doi: 10.1007/s00066-005-1416-5.
8
Does the management of bladder perforation during transurethral resection of superficial bladder tumors predispose to extravesical tumor recurrence?经尿道浅表膀胱肿瘤切除术中膀胱穿孔的处理是否会增加膀胱外肿瘤复发的风险?
J Urol. 2005 Jun;173(6):1908-11. doi: 10.1097/01.ju.0000158450.71497.ae.
9
[A clinical study of superficial bladder cancer with grade 3 components].
Hinyokika Kiyo. 1998 Jun;44(6):375-9.
10
[Iatrogenic tumor cell implantation in bladder cancer].
Urologe A. 1988 Mar;27(2):99-104.